Opinion of the Transparency Council – changes to the drug programme B.61
At its meeting on 25 July 2022 the Transparency Council adopted Opinion No. 118/2022 on the changes to the drug programme B.61 “Treatment of patients with early-onset nephropathic cystinosis (ICD-10: E72.0)”.
Publication with the minutes of the Transparency Council meeting